The FDA has approved oxycodone-naltrexone extended-release (ER) capsules (Troxyca ER, Pfizer) for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Oxycodone-naltrexone ER has properties that are expected to reduce abuse when crushed and administered by the oral and intranasal routes. However, abuse of oxycodone-naltrexone ER by these routes is still possible. It is the only oxycodone